Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

Evaluation of new drug combinations is needed to improve patients' prognosis in advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the safety and efficacy of the capecitabine–oxaliplatine combination (XELOX) in HCC patients. First-line chemotherapy with XELOX reg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Boige, V, Raoul, J-L, Pignon, J-P, Bouché, O, Blanc, J-F, Dahan, L, Jouve, J-L, Dupouy, N, Ducreux, M
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2007
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360397/
https://ncbi.nlm.nih.gov/pubmed/17876335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603956
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars